Propanc Reports Over 90% Tumor Inhibition for PRP

Propanc Biopharma's lead oncology candidate PRP has posted preclinical results that will draw scrutiny from development teams tracking differentiation-based alternatives to cytotoxic and RAS-targeted regimens in pancreatic ductal adenocarcinoma. In orthotopic and patient-derived xenograft models of advanced PDAC, three-times-weekly intravenous PRP delivered greater than 90% mean tumor growth inhibition versus vehicle controls (p < 0.001) and a median overall survival extension exceeding 2.5-fold in treated animals.

The dataset extends previously reported figures showing greater than 85% tumor growth inhibition and adds mechanistic detail relevant to translational planning. Investigators observed marked reduction in hepatic and peritoneal metastatic burden, suppression of epithelial-mesenchymal transition markers, decreased cancer-associated fibroblast activity, and reduced fibrosis within the tumor microenvironment. A combination signal is also present: PRP enhanced gemcitabine/nab-paclitaxel sensitivity in chemo-resistant PDAC cells, a finding that could inform dosing strategy in the planned clinical program.

PRP is a fixed-ratio combination of trypsinogen and chymotrypsinogen. Its proposed mechanism centers on promoting malignant-cell differentiation toward a more normal phenotype and targeting cancer stem cells, rather than inhibiting a specific oncogenic pathway. That distinction carries practical weight when read against the RASolute 302 Phase 3 data for Revolution Medicines' daraxonrasib, which achieved median overall survival of 13.2 months versus 6.6–6.7 months on chemotherapy in previously treated metastatic PDAC. Because approximately 90% of PDAC cases carry RAS mutations, RAS-targeted agents address a large but defined population; PRP's mechanism is not mutation-restricted, and the company holds FDA Orphan Drug Designation for pancreatic cancer.

For manufacturing and regulatory leads, the near-term operational picture is concrete. Propanc is progressing GMP manufacturing, pharmacokinetics assay validation, and clinical partnership agreements in support of a Phase 1b first-in-human study targeting approximately 40–45 patients with advanced solid tumors, with pancreatic cancer as a primary focus indication. A clinical trial application is expected, though the source does not specify a submission date. Limited prior compassionate-use experience with related proenzyme formulations has shown prolonged survival signals in advanced solid-tumor patients with no severe treatment-related adverse events reported, a safety profile that will inform the Phase 1b monitoring plan.

Completion of GMP manufacturing readiness and pharmacokinetics assay validation will represent the measurable checkpoints before a clinical trial application can advance.

Source: Propanc Biopharma via GlobeNewswire, 27 August 2026.